- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02946892
Effect of Carvedilol on Exercise Performance in Fontan Patients
January 11, 2021 updated by: Ryan Butts, University of Texas Southwestern Medical Center
This study evaluates the effect of carvedilol in patients who have undergone a Fontan heart operation.
All participants will receive carvedilol and placebo for 12 weeks.
Exercise tests will be performed at the end of each 12 week period.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Carvedilol is a well studied heart failure medication in adult heart failure that has been shown to improve outcomes.
However, it has not been studied in patients who have had a Fontan heart operation.
Study participants will receive either placebo or carvedilol for 12 weeks, at the end of the 12 weeks participants will perform an exercise test.
Then study participants will receive treatment with placebo or carvedilol for 12 weeks (opposite of what participants go the first 12 weeks) and will again perform an exercise test.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 35 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed consent of parent(s) or legal guardian; informed consent or assent of subject as applicable.
- Male or female children between the ages of 10 and 35 years with congenital heart disease that has been palliated with a Fontan circulation.
- Ability of perform a maximal exercise test as defined by a respiratory exchange ratio (RER) greater than 1.0 at the time of maximal exercise
Exclusion Criteria:
- The use of beta blockers within 2 months of randomization
- Patients actively listed for transplantation at time of entry into the study or anticipated to undergo heart transplantation, interventional catheterization, or corrective cardiac surgery during the 7 months following entry into the study
- Sustained or symptomatic ventricular dysrhythmias uncontrolled by drug therapy or the use of an implantable defibrillator, and/or significant cardiac conduction defects, e.g., 2nd degree or 3rd degree AV block, or sick sinus syndrome, unless a functioning pacemaker is in place
- Uncorrected obstructive or severe regurgitant valve disease, nondilated cardiomyopathy, or significant systemic ventricular outflow obstruction
- Known renovascular hypertension or evidence of pulmonary hypertension (pulmonary vascular resistance > 6 Wood units) unresponsive to vasodilator agents such as oxygen, nitroprusside, or nitric oxide
- History or current clinical evidence of moderate-to-severe fixed obstructive pulmonary disease or severe reactive airway diseases (e.g., asthma) requiring hospitalization within the past 2 years or patient currently using long-term inhaled bronchodilators
- Renal, hepatic, gastrointestinal, or biliary disorder that could impair absorption, metabolism or excretion of orally administered medication
- Concurrent terminal illness or other severe disease (e.g., active neoplasm) or other significant laboratory value(s) which, in the opinion of the investigator, could preclude participation or survival
- Endocrine disorders such as primary aldosteronism, pheochromocytoma, hyper- or hypothyroidism, insulin-dependent diabetes mellitus
- Unwillingness or inability to cooperate, or for the parents or guardians to give consent, or for the child to give assent, or any condition of sufficient severity to impair cooperation in the study
- Pregnancy or possible pregnancy at time of randomization, or female of child bearing potential who are lactating, or sexually active and not taking adequate contraceptive precautions (e.g., intrauterine device or oral contraceptives for 3 months prior to entry into the study)
- Use of an investigational drug within 30 days of randomization, or within 5 half-lives of the investigational drug (the longer period will apply)
- History of drug sensitivity or allergic reaction to alpha-blockers or ß-blockers
- Use of any of the following medications within two weeks of randomization: MAO inhibitors, Calcium channel blockers, alpha blockers, beta blockers, disopyramide, flecainide, encainide, moricizine, propafenone, sotalol, or beta adrenergic agonists
- Hospital admission for protein losing enteropathy or plastic bronchitis within 3 months of randomization
- Active and/or chronic protein losing enteropathy or plastic bronchitis (on inhaled medication to control the plastic bronchitis).
- Hypoalbuminemia defined as serum albumin <2.0g/dL
- Renal dysfunction defined as serum creatinine >2.0mg/dL
- Hepatic dysfunction defined as serum AST and/or ALT> 3 times upper limit of normal (approximately 120 IU/L however, will vary depending on age),
- Significant anemia or polycythemia defined as hemoglobin >18gm/dL or hemoglobin <7gm/dL
- Severely elevated serum BNP defined as BNP>300pg/ml
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Carvedilol
Study participants will receive carvedilol for 12 weeks
|
Carvedilol will be given for 12 weeks and then an exercise test will be performed
Other Names:
|
EXPERIMENTAL: Placebo
Study participants will receive placebo (sugar pill) for 12 weeks
|
Placebo will be given for 12 weeks and then an exercise test will be performed
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Peak Oxygen Uptake From Baseline Peak Oxygen Uptake
Time Frame: on week 12 and week 30 of the study
|
during exercise test on week 12 and week 30
|
on week 12 and week 30 of the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Peak Heart Rate
Time Frame: on week 12 and week 30 of the study
|
during exercise test on week 12 and week 30
|
on week 12 and week 30 of the study
|
Change in Oxygen Uptake at Anaerobic Threshold
Time Frame: on week 12 and week 30 of the study
|
during exercise test on week 12 and week 30
|
on week 12 and week 30 of the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 1, 2016
Primary Completion (ACTUAL)
December 1, 2019
Study Completion (ACTUAL)
January 1, 2020
Study Registration Dates
First Submitted
September 23, 2016
First Submitted That Met QC Criteria
October 25, 2016
First Posted (ESTIMATE)
October 27, 2016
Study Record Updates
Last Update Posted (ACTUAL)
January 22, 2021
Last Update Submitted That Met QC Criteria
January 11, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Congenital Abnormalities
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Univentricular Heart
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Protective Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Antioxidants
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Carvedilol
Other Study ID Numbers
- 062016-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Single Ventricle
-
Timothy Icenogle, MDWithdrawnSingle-ventricle | Failing Fontan Physiology | Failing Fontan | Single-ventricle Fontan | Single-ventricle PhysiologyUnited States
-
Barbara BurkhardtNot yet recruitingSingle-ventricleSwitzerland
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); The Methodist Hospital Research...Recruiting
-
HealthCore-NERINational Heart, Lung, and Blood Institute (NHLBI)CompletedSingle Ventricle PhysiologyUnited States
-
University of MichiganTerminated
-
Hacettepe UniversityCompleted
-
Washington University School of MedicineCompletedSingle Ventricle Fontan PalliationUnited States
-
Emory UniversityTerminatedAmbulatory Children With Single VentricleUnited States
-
Stanford UniversityVanderbilt University Medical Center; Adult Congenital Heart Association; Julie... and other collaboratorsNot yet recruitingSingle-ventricle | Heart Failure CongenitalUnited States
-
Mezzion Pharma Co. LtdRecruitingSingle Ventricle Heart DiseaseUnited States
Clinical Trials on Carvedilol
-
Chong Kun Dang PharmaceuticalCompletedHypertensionKorea, Republic of
-
Zunyi Medical CollegeUnknownChronic AppendicitisChina
-
E-DA HospitalTerminatedVariceal BleedingTaiwan
-
GlaxoSmithKlineCompletedMetabolic, CardiovascularUnited Kingdom
-
Andhra Medical CollegeCompleted
-
CTI-1, LLCGlaxoSmithKline; CTI Clinical Trial and Consulting ServicesCompletedCongestive Heart FailureUnited States
-
Institute of Liver and Biliary Sciences, IndiaRecruiting
-
Owen Chan, PhDTerminated
-
University of MinnesotaGlaxoSmithKlineCompletedPre-hypertensionUnited States
-
GlaxoSmithKlineCompletedHeart Failure, CongestiveJapan